Detalhe da pesquisa
1.
Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management.
J Oncol Pharm Pract
; 26(1): 74-92, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30917738
2.
Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate.
Cancer Chemother Pharmacol
; 72(2): 417-27, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23797686
3.
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.
J Clin Oncol
; 31(35): 4400-6, 2013 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24127448